Cargando…

Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients

BACKGROUND: Reproducibility of clinical and epidemiologic research is important to generalize findings and has increasingly been scrutinized. A recently published randomized trial, PIVOTAL, evaluated high vs low intravenous iron dosing strategies to manage anemia in hemodialysis patients in the UK....

Descripción completa

Detalles Bibliográficos
Autores principales: Karaboyas, Angelo, Morgenstern, Hal, Fleischer, Nancy L, Schaubel, Douglas E, Robinson, Bruce M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667704/
https://www.ncbi.nlm.nih.gov/pubmed/33204166
http://dx.doi.org/10.2147/CLEP.S283321
_version_ 1783610364961751040
author Karaboyas, Angelo
Morgenstern, Hal
Fleischer, Nancy L
Schaubel, Douglas E
Robinson, Bruce M
author_facet Karaboyas, Angelo
Morgenstern, Hal
Fleischer, Nancy L
Schaubel, Douglas E
Robinson, Bruce M
author_sort Karaboyas, Angelo
collection PubMed
description BACKGROUND: Reproducibility of clinical and epidemiologic research is important to generalize findings and has increasingly been scrutinized. A recently published randomized trial, PIVOTAL, evaluated high vs low intravenous iron dosing strategies to manage anemia in hemodialysis patients in the UK. Our objective was to assess the reproducibility of the PIVOTAL trial findings using data from a well-established cohort study, the Dialysis Outcomes and Practice Patterns Study (DOPPS). METHODS: To overcome the absence of randomization in the DOPPS, we applied the parametric g-formula, an extension of standardization to longitudinal data. We estimated the effect of a proactive high-dose vs reactive low-dose iron supplementation strategy on all-cause mortality (primary outcome), hemoglobin, two measures of iron concentration (ferritin and TSAT), and erythropoiesis-stimulating agent dose over 12 months of follow-up in 6325 DOPPS patients. RESULTS: Comparing high- vs low-iron dose strategies, the 1-year mortality risk difference was 0.020 (95% CI: 0.008, 0.031) and risk ratio was 1.20 (95% CI: 1.07, 1.33), compared with null 1-year findings in the PIVOTAL trial. Differences in secondary outcomes were directionally consistent but of lesser magnitude than in the PIVOTAL trial. CONCLUSION: Our findings are somewhat consistent with the recent PIVOTAL trial, with discrepancies potentially attributable to model misspecification and differences between the two study populations. In addition to the importance of our results to nephrologists and hence hemodialysis patients, our analysis illustrates the utility of the parametric g-formula for generalizing results and comparing complex and dynamic treatment strategies using observational data.
format Online
Article
Text
id pubmed-7667704
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76677042020-11-16 Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients Karaboyas, Angelo Morgenstern, Hal Fleischer, Nancy L Schaubel, Douglas E Robinson, Bruce M Clin Epidemiol Original Research BACKGROUND: Reproducibility of clinical and epidemiologic research is important to generalize findings and has increasingly been scrutinized. A recently published randomized trial, PIVOTAL, evaluated high vs low intravenous iron dosing strategies to manage anemia in hemodialysis patients in the UK. Our objective was to assess the reproducibility of the PIVOTAL trial findings using data from a well-established cohort study, the Dialysis Outcomes and Practice Patterns Study (DOPPS). METHODS: To overcome the absence of randomization in the DOPPS, we applied the parametric g-formula, an extension of standardization to longitudinal data. We estimated the effect of a proactive high-dose vs reactive low-dose iron supplementation strategy on all-cause mortality (primary outcome), hemoglobin, two measures of iron concentration (ferritin and TSAT), and erythropoiesis-stimulating agent dose over 12 months of follow-up in 6325 DOPPS patients. RESULTS: Comparing high- vs low-iron dose strategies, the 1-year mortality risk difference was 0.020 (95% CI: 0.008, 0.031) and risk ratio was 1.20 (95% CI: 1.07, 1.33), compared with null 1-year findings in the PIVOTAL trial. Differences in secondary outcomes were directionally consistent but of lesser magnitude than in the PIVOTAL trial. CONCLUSION: Our findings are somewhat consistent with the recent PIVOTAL trial, with discrepancies potentially attributable to model misspecification and differences between the two study populations. In addition to the importance of our results to nephrologists and hence hemodialysis patients, our analysis illustrates the utility of the parametric g-formula for generalizing results and comparing complex and dynamic treatment strategies using observational data. Dove 2020-11-11 /pmc/articles/PMC7667704/ /pubmed/33204166 http://dx.doi.org/10.2147/CLEP.S283321 Text en © 2020 Karaboyas et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Karaboyas, Angelo
Morgenstern, Hal
Fleischer, Nancy L
Schaubel, Douglas E
Robinson, Bruce M
Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients
title Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients
title_full Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients
title_fullStr Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients
title_full_unstemmed Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients
title_short Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients
title_sort replicating randomized trial results with observational data using the parametric g-formula: an application to intravenous iron treatment in hemodialysis patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667704/
https://www.ncbi.nlm.nih.gov/pubmed/33204166
http://dx.doi.org/10.2147/CLEP.S283321
work_keys_str_mv AT karaboyasangelo replicatingrandomizedtrialresultswithobservationaldatausingtheparametricgformulaanapplicationtointravenousirontreatmentinhemodialysispatients
AT morgensternhal replicatingrandomizedtrialresultswithobservationaldatausingtheparametricgformulaanapplicationtointravenousirontreatmentinhemodialysispatients
AT fleischernancyl replicatingrandomizedtrialresultswithobservationaldatausingtheparametricgformulaanapplicationtointravenousirontreatmentinhemodialysispatients
AT schaubeldouglase replicatingrandomizedtrialresultswithobservationaldatausingtheparametricgformulaanapplicationtointravenousirontreatmentinhemodialysispatients
AT robinsonbrucem replicatingrandomizedtrialresultswithobservationaldatausingtheparametricgformulaanapplicationtointravenousirontreatmentinhemodialysispatients